ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2019年07月31日 14時41分
Source:
Eisai
エーザイ、2020年3月期配当予想の修正（増配）に関するお知らせ
東京, 2019年07月31日 - (JCN Newswire) - 当社は、2019年7月31日開催の取締役会において、2020年3月期第2四半期末（中間）配当の予想について、下記の通り、修正（増配）することを決議しましたので、お知らせします。
1. 配当予想の修正について
2020年3月期第2四半期末（中間）配当の予想の修正（増配）
年間配当金（円）
第2四半期末／期末／合計
前回予想（2019年5月13日公表）70円00銭／80円00銭／150円00銭
今回修正予想 80円00銭／80円00銭／160円00銭
当期実績 －／－／－
前期実績（2019年3月期）70円00銭／80円00銭／150円00銭
2. 修正の内容
当社は、主要なステークホルダーズである患者様と生活者の皆様、株主の皆様および社員の価値増大をはかるとともに良好な関係の発展・維持に努めています。
配当につきましては、長期的なバランスシートマネジメントに依拠した「最適資本構成に基づく最適配当政策」を志向しており、連結業績、DOE（親会社所有者帰属持分配当率）およびフリー・キャッシュ・フローを総合的に勘案し、「シグナリング効果」も考慮して、株主の皆様へ継続的・安定的な配当を実施します。配当のKPIとしては、連結純資産に対する配当の比率を示すDOEを採択しています。
今回、これらの配当方針、ならびに好調な業績に基づく強固なバランスシートを勘案し、前回発表（2019年5月13日）の2020年3月期第2四半期末（中間）配当金予想を10円増配の80円に修正します。2010年3月期以来となる増配により期末配当金予想80円と合わせ、年間配当金予想は160円（前回予想は150円）、2020年3月期通期業績予想に基づくDOEは7.1％となる見込みです。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2019/news201959.html
概要：エーザイ株式会社
詳細はwww.eisai.co.jpをご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Hitachi Energy Japan Recognized as a 2026 Health & Productivity Management Outstanding Organization (Large Enterprise Category)
Mar 16, 2026 16:20 JST
Fujitsu Japan and Teikyo University Hospital launch joint proof of concept to build mechanism for data analysis and referred-patient management
Mar 16, 2026 12:55 JST
Mitsubishi Shipbuilding Completes Handover of WAKASHIO MARU Training Ship for National Institute of Technology, Toyama College
Mar 13, 2026 16:01 JST
Mitsubishi Heavy Industries to Introduce 10MW-Class Centrifugal Chiller for Next-Generation AI Data Centers in North America
Mar 13, 2026 14:10 JST
Spritzer Sparkling's 'Serikan Raya, Sparkling-kan Suasana' Festive Fusion Message Promotes Togetherness and Tradition with a Light, Modern Twist
Mar 13, 2026 12:45 JST
Hitachi to deliver the world's first 550 kV gas-insulated switchgear in which the entire equipment is SF(6)-free to Chubu Electric Power Grid
Mar 12, 2026 19:40 JST
Honda Announces Losses Associated with Reassessment of Automobile Electrification Strategy; Revision to Forecast for Consolidated Financial Results; and Future Direction
Mar 12, 2026 19:02 JST
Japantastics Introduces the World of Kodaimoji, Bringing Ancient Characters into Modern Spaces
Mar 12, 2026 19:00 JST
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
Mar 12, 2026 17:21 JST
NEC Develops Physical AI That Anticipates Human Movement and Psychological States
Mar 12, 2026 16:41 JST
NEC and The University of Tokyo calculate carbon accumulation rates in Malaysian national park with a 9.4% margin of error
Mar 12, 2026 12:02 JST
Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY(R) in Mainland China, Addressing Unmet Need in Moderately to Severely Active Ulcerative Colitis
Mar 11, 2026 20:15 JST
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
Mar 11, 2026 12:07 JST
Fujitsu launches Japan's first defense tech open innovation program
Mar 10, 2026 11:45 JST
Fujitsu and DT-Axis collaborate to advance digital health
Mar 09, 2026 13:32 JST
Hong Kong Completes First Green Methanol Bunkering, Driving Green Transformation of Its International Shipping Hub
Mar 08, 2026 16:05 JST
International Women's Day: Why Menopause May Be a Missed Cardiovascular Risk Window
Mar 06, 2026 20:00 JST
TANAKA Develops World's First High-Performance Palladium Hydrogen Permeable Membrane Exhibiting High Hydrogen Purification Performance at Temperatures around 100 degrees C
Mar 05, 2026 22:00 JST
Honda to Begin Sales of Two U.S.-built Vehicles in Japan
Mar 05, 2026 16:47 JST
DOCOMO's New Haptic-sharing System Enables Fans to Feel Closer to Idols
Mar 05, 2026 16:38 JST
More Latest Release >>
Related Release
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
3/12/2026 5:21:00 PM JST
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
3/11/2026 12:07:00 PM JST
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
3/2/2026 9:49:00 AM JST
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
2/16/2026 2:03:00 PM JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
2/10/2026 1:34:00 PM JST
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
2/6/2026 11:31:00 AM JST
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
1/26/2026 11:37:00 AM JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
1/21/2026 4:44:00 PM JST
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
1/13/2026 9:50:00 AM JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
1/6/2026 10:43:00 AM JST
More Press release >>